Innate Pharma (IPHA) Non-Current Debt (2017 - 2025)

Innate Pharma has reported Non-Current Debt for 9 years, with the latest figure at $16.0 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt fell 32.69% year-over-year to $16.0 million; the trailing twelve-month figure through Dec 2025 stood at $16.0 million (down 32.69% YoY), and the FY2025 full-year result was $16.0 million, down 32.69% from the prior year.
• Non-Current Debt for Q4 2025 stood at $16.0 million, down from $20.5 million in the prior quarter.
• The five-year high for Non-Current Debt was $41.0 million in Q4 2022, with the low at $13.4 million in Q2 2022.
• Historically, Non-Current Debt has averaged $24.8 million across 5 years, with a median of $22.1 million in 2024.
• Annual changes were most pronounced in 2021 — Non-Current Debt slumped 99.9% — and 2023, when it soared 187.85%.
• Innate Pharma's Non-Current Debt stood at $15.4 million in 2021, then jumped by 165.18% to $41.0 million in 2022, then decreased by 18.69% to $33.3 million in 2023, then decreased by 28.5% to $23.8 million in 2024, then sank by 32.69% to $16.0 million in 2025.
• The last three Non-Current Debt figures came in at $16.0 million (Q4 2025), $20.5 million (Q2 2025), and $23.8 million (Q4 2024), per Business Quant data.